Endostatin is a protein that is located in most Basement Membranes (BMs) in the body, such as vascular basement membranes. Some clinical studies have validated the significant survival benefits of recombinant human endostatin in treating late-stage Non-Small-Cell Lung Carcinoma (NSCLC).
MARKET DYNAMICS
The recombinant human endostatin market is driving due to government initiatives to reduce prices of anticancer drugs. However, increasing challenges in significant production of recombinant human endostatin is expected to hinder the market growth. Moreover, increasing research and development activities for identifying potential uses of recombinant human endostatin is expected to propel growth of the market.
MARKET SCOPE
The "Recombinant Human Endostatin Market Analysis to 2028" is a specialized and in-depth study of the healthcare industry with a special focus on the global market trend analysis. The report aims to provide an overview of recombinant human endostatin market with detailed market segmentation by application. The recombinant human endostatin market is expected to witness high growth during the forecast period. The report provides key statistics on the market status of the leading players in recombinant human endostatin market and offers key trends and opportunities in the market.
MARKET SEGMENTATION
The recombinant human endostatin market is segmented on the basis of application. On the basis of application, the market is categorized as medical application and scientific application.
REGIONAL FRAMEWORK
The report provides a detailed overview of the industry including both qualitative and quantitative information. It provides overview and forecast of the recombinant human endostatin market based on various segments. It also provides market size and forecast estimates from year 2020 to 2028 with respect to five major regions, namely; North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South & Central America. The recombinant human endostatin market by each region is later sub-segmented by respective countries and segments. The report covers analysis and forecast of 18 countries globally along with current trend and opportunities prevailing in the region.
The report analyzes factors affecting recombinant human endostatin market from both demand and supply side and further evaluates market dynamics affecting the market during forecast period i.e., drivers, restraints, opportunities, and future trend. The report also provides exhaustive PEST analysis for all five regions namely; North America, Europe, APAC, MEA and South & Central America after evaluating political, economic, social and technological factors effecting the recombinant human endostatin market in these regions.
MARKET PLAYERS
The report covers key developments in the recombinant human endostatin market as organic and inorganic growth strategies. Various companies are focusing on organic growth strategies such as product launches, product approvals and others such as patents and events. Inorganic growth strategies witnessed in the market were acquisitions, and partnership & collaborations. These activities have paved way for expansion of business and customer base of market players. The market players from recombinant human endostatin market are anticipated to have lucrative growth opportunities in the future with the rising demand for recombinant human endostatin in the global market. Below mentioned is the list of few companies engaged in the recombinant human endostatin market.
The report also includes the profiles of key players in recombinant human endostatin market along with their SWOT analysis and market strategies. In addition, the report focuses on leading industry players with information such as company profiles, components and services offered, financial information of last 3 years, key development in past five years.
- Biocon
- FUJIFILM KYOWA KIRIN BIOLOGICS Co., Ltd.
- Genexine, Inc.
- Hetero
- Novus Biologicals
- Onyx Pharmaceuticals, Inc.,
- PeproTech, Inc.
- Pfizer Inc.
- Thermo Fisher Scientific
- Yantai Medgenn Ltd.
The Insight Partner's dedicated research and analysis team consists of experienced professionals with advanced statistical expertise and offers various customization options in the existing study.